James E. D. Thaventhiran

James E. D. Thaventhiran

Auto-generated profile, based on publicly available information

James E. D. Thaventhiran

Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
KCKeren J. Carss
Keren J. Carss
GAGavin Arno
Gavin Arno
MEMarie Erwood
Marie Erwood
JSJonathan Stephens
Jonathan Stephens
ASAlba Sanchis-Juan
Alba Sanchis-Juan
PYPing Yu
Ping Yu

1 June 2021 in Immunity
Verified
Journal Article
Open access
LBLaura Bergamaschi
Laura Bergamaschi
FMFederica Mescia
Federica Mescia
LTLorinda Turner
Lorinda Turner
AHAimee L. Hanson
Aimee L. Hanson
PKPrasanti Kotagiri
Prasanti Kotagiri
KSKenneth G.C. Smith
Kenneth G.C. Smith
The kinetics of the immune changes in COVID-19 across severity groups have not been rigorously assessed. Using immunophenotyping, RNA sequencing and serum cytokine analysis, we analyzed serial samples from 207 SARS-CoV2-infected individuals with a range of disease severities over 12 weeks from symptom onset. An early robust bystander CD8+ T cell immune response, without systemic inflammation, characterized asymptomatic or mild disease. Hospitalized individuals had delayed bystander responses and systemic inflammation that was already evident near symptom onset, indicating that immunopathology may be inevitable in some individuals. Viral load did not correlate with this early pathological response, but did correlate with subsequent disease severity. Immune recovery is complex, with profound persistent cellular abnormalities in severe disease correlating with altered inflammatory responses, with signatures associated with increased oxidative phosphorylation replacing those driven by cytokines tumor necrosis factor (TNF) and interleukin (IL)-6. These late immunometabolic and immune defects may have clinical implications.

30 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DBDaniele Biasci
Daniele Biasci
JNJudy Needham
Judy Needham
CCClaire M. Connell
Claire M. Connell
ZWZhikai Wang
Zhikai Wang
YGYa Gao
Ya Gao
DJDuncan I. Jodrell
Duncan I. Jodrell
Significance: Patients with microsatellite stable (MSS) pancreatic (PDA) or colorectal cancer (CRC) do not respond to immunotherapy with inhibitors of T cell checkpoints. A possible explanation is suggested by finding that cancer cells in these tumors are coated with the chemokine, CXCL12, and that stimulation of CXCR4, the CXCL12 receptor on immune cells, suppresses directed migration mediated by other chemokine receptors on these cells. We assessed the relevance of these findings by treating patients for seven days with continuous infusion of AMD3100/Plerixafor, a CXCR4 inhibitor. Comparison of pre- and end-of-treatment paired biopsies of metastatic lesions by transcriptomic analysis revealed that AMD3100 induced an integrated immune response that is predictive of a clinical response to T cell checkpoint inhibition.

1 October 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
PTPaul Tuijnenburg
Paul Tuijnenburg
HAHana Lango Allen
Hana Lango Allen
SBSiobhan O. Burns
Siobhan O. Burns
DGDaniel Greene
Daniel Greene
MJMachiel H. Jansen
Machiel H. Jansen
CWChristopher Watt
Christopher Watt
The genetic cause of primary immunodeficiency disease (PID) carries prognostic information. We conducted a whole-genome sequencing study assessing a large proportion of the NIHR BioResource-Rare Diseases cohort. In the predominantly European study population of principally sporadic unrelated PID cases (n = 846), a novel Bayesian method identified nuclear factor κB subunit 1 (NFKB1) as one of the genes most strongly associated with PID, and the association was explained by 16 novel heterozygous truncating, missense, and gene deletion variants. This accounted for 4% of common variable immunodeficiency (CVID) cases (n = 390) in the cohort. Amino acid substitutions predicted to be pathogenic were assessed by means of analysis of structural protein data. Immunophenotyping, immunoblotting, and ex vivo stimulation of lymphocytes determined the functional effects of these variants. Detailed clinical and pedigree information was collected for genotype-phenotype cosegregation analyses. Both sporadic and familial cases demonstrated evidence of the noninfective complications of CVID, including massive lymphadenopathy (24%), unexplained splenomegaly (48%), and autoimmune disease (48%), features prior studies correlated with worse clinical prognosis. Although partial penetrance of clinical symptoms was noted in certain pedigrees, all carriers have a deficiency in B-lymphocyte differentiation. Detailed assessment of B-lymphocyte numbers, phenotype, and function identifies the presence of an increased CD21low B-cell population. Combined with identification of the disease-causing variant, this distinguishes between healthy subjects, asymptomatic carriers, and clinically affected cases. We show that heterozygous loss-of-function variants in NFKB1 are the most common known monogenic cause of CVID, which results in a temporally progressive defect in the formation of immunoglobulin-producing B cells.

6 May 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JTJames E. D. Thaventhiran
James E. D. Thaventhiran
HAHana Lango Allen
Hana Lango Allen
OBOliver S. Burren
Oliver S. Burren
WRWilliam Rae
William Rae
DGDaniel Greene
Daniel Greene
KSKenneth G. C. Smith
Kenneth G. C. Smith

6 December 2023 in Nature
Verified
Journal Article
Open access
PDF file
TMThomas E. Mulroney
Thomas E. Mulroney
TPTuija Pöyry
Tuija Pöyry
JYJuan Carlos Yam-Puc
Juan Carlos Yam-Puc
MRMaria Rust
Maria Rust
RHRobert F. Harvey
Robert F. Harvey
AWAnne E Willis
Anne E Willis
In vitro-transcribed (IVT) mRNAs are modalities that can combat human disease, exemplified by their use as vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). IVT mRNAs are transfected into target cells, where they are translated into recombinant protein, and the biological activity or immunogenicity of the encoded protein exerts an intended therapeutic effect1,2. Modified ribonucleotides are commonly incorporated into therapeutic IVT mRNAs to decrease their innate immunogenicity3–5, but their effects on mRNA translation fidelity have not been fully explored. Here we demonstrate that incorporation of N1-methylpseudouridine into mRNA results in +1 ribosomal frameshifting in vitro and that cellular immunity in mice and humans to +1 frameshifted products from BNT162b2 vaccine mRNA translation occurs after vaccination. The +1 ribosome frameshifting observed is probably a consequence of N1-methylpseudouridine-induced ribosome stalling during IVT mRNA translation, with frameshifting occurring at ribosome slippery sequences. However, we demonstrate that synonymous targeting of such slippery sequences provides an effective strategy to reduce the production of frameshifted products. Overall, these data increase our understanding of how modified ribonucleotides affect the fidelity of mRNA translation, and although there are no adverse outcomes reported from mistranslation of mRNA-based SARS-CoV-2 vaccines in humans, these data highlight potential off-target effects for future mRNA-based therapeutics and demonstrate the requirement for sequence optimization.